Skip to content

Vitamin D for treating autism

Vitamin D for treating autism, a controlled clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201405273930N34
Enrollment
30
Registered
2014-10-17
Start date
2014-08-07
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorder. Childhood autism

Interventions

Intervention 1: An intramuscular vitamin D 300,000 IU repeated one week later plus risperidone (0.5 to 3 mg/day). Intervention 2: control group will receive vitamin D.
Treatment - Drugs
An intramuscular vitamin D 300,000 IU repeated one week later plus risperidone (0.5 to 3 mg/day)
control group will receive vitamin D

Sponsors

Vice chancellor for research, Shiraz University of Medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Autism according to DSM-IV diagnostic criteria; aged 3 to 18 years old; and serum level of vitamin D less than 25 ng/mL. Exclusion Criteria: primary diagnosis of a psychotic disorder; active substance abuse or dependence; history of allergy to vitamin D; and unstable medical condition.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical behavioral symptoms. Timepoint: Every 4 weeks. Method of measurement: Abbrant Behavior Checklist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeysam Hosini

Shiraz University of Medical sciences

mey30_ben@yahoo.com+98 71 1627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026